These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34235096)

  • 1. CD38-Directed Therapies for Management of Multiple Myeloma.
    Hashmi H; Husnain M; Khan A; Usmani SZ
    Immunotargets Ther; 2021; 10():201-211. PubMed ID: 34235096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
    Franssen LE; Stege CAM; Zweegman S; van de Donk NWCJ; Nijhof IS
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
    Radocha J; van de Donk NWCJ; Weisel K
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.
    Richter J; Sanchez L; Thibaud S
    Semin Oncol; 2020; 47(2-3):155-164. PubMed ID: 32446599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
    Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
    Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab for the treatment of multiple myeloma.
    Touzeau C; Moreau P
    Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status and future prospects of immunotherapy for multiple myeloma].
    Imai Y
    Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab in untreated newly diagnosed multiple myeloma.
    Abdallah N; Kumar SK
    Ther Adv Hematol; 2019; 10():2040620719894871. PubMed ID: 31903177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isatuximab for the treatment of multiple myeloma.
    Goldsmith SR; Liu L; Covut F
    Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD38 antibodies in multiple myeloma: back to the future.
    van de Donk NWCJ; Richardson PG; Malavasi F
    Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
    van de Donk NWCJ
    Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg.
    De Wilde S; Plawny L; Berchem G
    Hematology; 2023 Dec; 28(1):2182098. PubMed ID: 36880781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
    Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.